ES2546465T3 - Inhibidores de N1/N2-lactama acetil-CoA carboxilasa - Google Patents

Inhibidores de N1/N2-lactama acetil-CoA carboxilasa Download PDF

Info

Publication number
ES2546465T3
ES2546465T3 ES11784783.0T ES11784783T ES2546465T3 ES 2546465 T3 ES2546465 T3 ES 2546465T3 ES 11784783 T ES11784783 T ES 11784783T ES 2546465 T3 ES2546465 T3 ES 2546465T3
Authority
ES
Spain
Prior art keywords
inhibitors
coa
compound
formula
acc2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11784783.0T
Other languages
English (en)
Spanish (es)
Inventor
Scott William Bagley
Robert Lee Dow
David Andrew Griffith
Aaron Christopher Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Inc filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2546465T3 publication Critical patent/ES2546465T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
ES11784783.0T 2010-10-29 2011-10-18 Inhibidores de N1/N2-lactama acetil-CoA carboxilasa Active ES2546465T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40812710P 2010-10-29 2010-10-29
US408127P 2010-10-29
US201161531744P 2011-09-07 2011-09-07
US201161531744P 2011-09-07
PCT/IB2011/054643 WO2012056372A1 (en) 2010-10-29 2011-10-18 N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS

Publications (1)

Publication Number Publication Date
ES2546465T3 true ES2546465T3 (es) 2015-09-23

Family

ID=44993633

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11784783.0T Active ES2546465T3 (es) 2010-10-29 2011-10-18 Inhibidores de N1/N2-lactama acetil-CoA carboxilasa

Country Status (26)

Country Link
US (3) US8859773B2 (enExample)
EP (2) EP2632925B1 (enExample)
JP (2) JP5647356B2 (enExample)
KR (2) KR20150006899A (enExample)
CN (2) CN103189377B (enExample)
AR (1) AR083578A1 (enExample)
AU (1) AU2011322117B2 (enExample)
BR (1) BR112013010310A2 (enExample)
CA (1) CA2815169C (enExample)
CY (1) CY1116405T1 (enExample)
DK (1) DK2632925T3 (enExample)
ES (1) ES2546465T3 (enExample)
HK (1) HK1209733A1 (enExample)
HU (1) HUE025078T2 (enExample)
IL (1) IL225779A0 (enExample)
MX (1) MX2013004733A (enExample)
NZ (1) NZ609527A (enExample)
PL (1) PL2632925T3 (enExample)
PT (1) PT2632925E (enExample)
RU (1) RU2540337C2 (enExample)
SG (1) SG189883A1 (enExample)
SI (1) SI2632925T1 (enExample)
TW (3) TWI441823B (enExample)
UY (1) UY33694A (enExample)
WO (1) WO2012056372A1 (enExample)
ZA (1) ZA201303882B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2632925T3 (pl) * 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
PT2953942T (pt) 2013-02-06 2018-01-17 Bayer Cropscience Ag Derivados de pirazol substituídos com halogéneo como agentes pesticidas
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
CN104230922B (zh) 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112016017527B1 (pt) 2014-01-03 2021-01-05 Bayer Animal Health Gmbh compostos, usos de compostos, composições farmacêuticas, processo para produzir composições e método não terapêutico para controlar pragas
CN104844509A (zh) * 2014-02-14 2015-08-19 河南工业大学 一种条件温和无金属参与的胺基喹啉衍生物的制备方法
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
CN106749002A (zh) * 2015-02-12 2017-05-31 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
WO2016142394A1 (de) 2015-03-10 2016-09-15 Bayer Animal Health Gmbh Pyrazolyl-derivate als schädlingsbekämpfungsmittel
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
UA125592C2 (uk) 2017-03-16 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
MX387359B (es) 2017-03-16 2025-03-18 Bristol Myers Squibb Co Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos.
JP7129420B6 (ja) 2017-03-30 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１阻害剤としてのイソキノリン
HUE061885T2 (hu) 2017-11-21 2023-08-28 Pfizer 4-(4-(4-(1-Izopropil-7-oxo-1,4,6,6,7-tetrahidrospiro[indazol-5,4'-piperidin] -1'-karbonil)-6-metoxipiridin-2-il)-benzoesav kristályos 2-amino-2-(hidroximetil)-propán-1,3-diol sója
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN109824669A (zh) * 2018-12-21 2019-05-31 西南大学 哌啶螺环酒石酸类化合物制备及应用
WO2021231191A1 (en) * 2020-05-12 2021-11-18 Merck Sharp & Dohme Corp. Factor xi activation inhibitors
CN115666558A (zh) * 2020-05-21 2023-01-31 盐野义制药株式会社 脂肪性肝病的治疗用药物
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
WO2022272036A1 (en) * 2021-06-25 2022-12-29 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof
CN120019059A (zh) * 2022-07-29 2025-05-16 辉瑞公司 新型acc抑制剂
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor
WO2025190395A2 (en) * 2024-03-14 2025-09-18 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002100A (en) 1932-06-27 1935-05-21 Smith Sheffield Shock absorber
JPS4925673B1 (enExample) * 1970-05-22 1974-07-02
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
JP4104983B2 (ja) 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
BR0212123A (pt) 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
MXPA04007083A (es) 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
ES2327857T3 (es) 2004-05-12 2009-11-04 Pfizer Products Inc. Derivados de prolina y su uso como inhibidores de la dipeptidil peptidasa iv.
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
BRPI0510273A (pt) 2004-05-25 2007-10-30 Pfizer Prod Inc derivados de tetraazabenzo[e]azuleno e análogos destes
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US7410976B2 (en) 2005-07-19 2008-08-12 Merck & Co., Inc. Spirochromanone derivatives
EP1911753A1 (en) 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
EP1951251B1 (en) 2005-11-18 2010-12-29 Merck Sharp & Dohme Corp. Spirohydantoin aryl cgrp receptor antagonists
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
EP2097420B1 (en) 2006-11-29 2012-04-04 Pfizer Products Inc. Spiroketone inhibitors of acetyl-coa carboxylase
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (ja) 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited 複素環化合物
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2297163B1 (en) 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
WO2010002010A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
US8110570B2 (en) 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
WO2010013161A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ATE540040T1 (de) 2008-08-28 2012-01-15 Pfizer Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
WO2010128425A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
CA2778886C (en) 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2778316A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
PL2632925T3 (pl) * 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA

Also Published As

Publication number Publication date
TWI507406B (zh) 2015-11-11
EP2632925A1 (en) 2013-09-04
SI2632925T1 (sl) 2015-07-31
JP5647356B2 (ja) 2014-12-24
DK2632925T3 (en) 2015-06-29
EP2632925B1 (en) 2015-05-27
US20150152109A1 (en) 2015-06-04
AU2011322117B2 (en) 2015-01-22
CN104774205A (zh) 2015-07-15
UY33694A (es) 2012-05-31
AR083578A1 (es) 2013-03-06
CA2815169C (en) 2015-10-06
KR101529404B1 (ko) 2015-06-26
WO2012056372A1 (en) 2012-05-03
EP2952514A1 (en) 2015-12-09
KR20140014078A (ko) 2014-02-05
JP2015057416A (ja) 2015-03-26
US20120108619A1 (en) 2012-05-03
RU2540337C2 (ru) 2015-02-10
KR20150006899A (ko) 2015-01-19
SG189883A1 (en) 2013-06-28
CA2815169A1 (en) 2012-05-03
MX2013004733A (es) 2013-07-02
IL225779A0 (en) 2013-06-27
TW201531472A (zh) 2015-08-16
CN103189377B (zh) 2015-02-25
BR112013010310A2 (pt) 2016-11-29
AU2011322117A1 (en) 2013-05-02
US8993586B2 (en) 2015-03-31
TW201302751A (zh) 2013-01-16
JP2013542218A (ja) 2013-11-21
HK1186724A1 (en) 2014-03-21
US20150025098A1 (en) 2015-01-22
US8859773B2 (en) 2014-10-14
ZA201303882B (en) 2014-02-26
TW201418256A (zh) 2014-05-16
PL2632925T3 (pl) 2015-10-30
RU2013116924A (ru) 2014-12-10
CN103189377A (zh) 2013-07-03
PT2632925E (pt) 2015-09-01
NZ609527A (en) 2014-03-28
CY1116405T1 (el) 2017-02-08
US9181252B2 (en) 2015-11-10
HK1209733A1 (en) 2016-04-08
HUE025078T2 (en) 2016-01-28
TWI441823B (zh) 2014-06-21

Similar Documents

Publication Publication Date Title
ES2546465T3 (es) Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
RU2719422C2 (ru) Необязательно конденсированные гетероциклил-замещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний
US20240307537A1 (en) Methods and Compositions for Treating Cancer
US20250345445A1 (en) Antibody-drug conjugate and use thereof
JP2011521940A (ja) ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
CA2825098A1 (en) Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
KR20140015511A (ko) 아세틸-CoA 카복실라아제 억제제로 사용하기 위한 피라졸로스피로케톤 유도체
TW201716406A (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
AU2017375687B2 (en) N-methyl-D-aspartate receptor allosteric modulators and methods for their use
ES2775614T3 (es) Sales de derivado de quinazolina y método de preparación de las mismas
US20120225900A1 (en) N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
US12195465B2 (en) Macrocyclic heterocycles and uses thereof
US9958434B2 (en) Fluorescent probe sensing tyrosine kinase and use thereof
US20240270736A1 (en) Macrocyclic heterocycles and uses thereof
EP4286386A1 (en) Salt form and crystal form of pyrazole substituted imidazo[1,2- a]quinoxaline derivative
CN104069123B (zh) 黄尿酸衍生物药物组合物及其相关方法
KR20140004676A (ko) 영상화제
WO2025011621A1 (zh) Polq抑制剂化合物和抗癌治疗剂或者放射疗法的组合
US6420563B1 (en) Small molecule modulators of G protein-coupled receptor six
EP4265274A1 (en) B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
EP3974438A1 (en) Fluorescent probe for use in detection of brain tumor
US20240109890A1 (en) Bridged heterocyclyl-substituted pyrimidine compounds, preparation method and medical use thereof
Huang et al. Parallel synthesis and biological evolution of quinic acid derivatives as immuno-suppressing agents against T-cell receptors
EA045554B1 (ru) Ингибитор fgfr4 и его применение
KR20120109824A (ko) Ｐａｕｆ 및 그의 결합 파트너를 상호작용을 이용한 암 치료제의 스크리닝 방법